All Oncology News

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

The FDA has removed the REMS program for vandetanib for the treatment of patients with medullary thyroid cancer.

Atebimetinib plus modified gemcitabine/nab-paclitaxel continued to elicit high OS rates in patients with treatment-naive pancreatic cancer.

The FDA approved imlunestrant for ER-positive, HER2-negative advanced or metastatic ESR1-mutated breast cancer following endocrine therapy.

Mitazalimab plus mFOLFIRINOX demonstrated encouraging survival outcomes in previously untreated metastatic pancreatic cancer.

Through a new agreement, nurse scientists from Dana-Farber will become Northeastern faculty members, bringing oncology nursing science into the classroom.

China’s NMPA has accepted for review a new drug application for A400/EP0031 in patients with RET fusion–positive non–small cell lung cancer.

Utidelone injection has received orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Real-world data highlighted differences in the timing and severity of belzutifan-related toxicities in VHL-associated tumors and sporadic RCC.

Dana M. Chase, MD, discusses the effect of the frontline dostarlimab plus chemotherapy on the recurrent endometrial cancer landscape.

The SCOPE score was predictive of response, toxicity, and survival outcomes in patients with relapsed/refractory myeloma receiving BCMA CAR T-cell therapy.

Alnodesertib has received fast track designation from the FDA for patients with ATM-negative metastatic colorectal cancer.

Frontline T-DXd plus pertuzumab is under FDA priority review for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

The collaboration blends LSU Health New Orleans’s robust research capabilities with IIT Madras’ technology innovation to drive global health impact.

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Theresa Medina, MD, discusses 5-year C-144-01 results with lifileucel in advanced melanoma.

A panel of hematologic cancer experts discusses data on GVHD management from the 2025 SOHO Annual Meeting.

Brian Slomovitz, MD, spotlights key advancements in disease management and prevention during Gynecologic Cancer Awareness Month.

Asad Dean, MD, discusses the evolving role of pirtobrutinib in chronic lymphocytic leukemia.

OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.

IberDd improved MRD negativity rates vs DVd in patients with relapsed/refractory multiple myeloma.

Tracy Battaglia, MD, MPH, joined Yale Cancer Center’s Community Outreach and Engagement as associate director.

INESSS has issued a positive recommendation for the reimbursement of subcutaneous nivolumab across all Health Canada–authorized solid tumor indications.

Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

CHMP has recommended the approval of selumetinib for symptomatic, inoperable plexiform neurofibromas (PNs) in adult neurofibromatosis type 1.

Manali Kamdar, MD, discusses advances with CAR T-cell therapy in B-cell malignancies and the monitoring needs for CRS and ICANS that affect patient access.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.